Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study

Veronica B. Ajewole, James E. Cox, Joshua T. Swan, Soumya G. Chikermane, Beverly Lamoth, Tomona Iso, Laura O. Okolo, Christen L. Ford, Amy M. Schneider, Eleanor C. Hobaugh, Kelty R. Baker

Research output: Contribution to journalArticle

Abstract

Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) may necessitate chemotherapy dose reduction, delay, or discontinuation. This pilot study tested feasibility of patient enrollment, CIPN screening, and data collection in cancer patients for a future clinical study that will assess the safety and efficacy of an intervention that may prevent CIPN. Methods: This prospective, observational, single-center, pilot study included adults with newly diagnosed lymphoma or multiple myeloma receiving neurotoxic chemotherapy. Patients were enrolled between September 2016 and February 2017. The Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire was completed by patients at 3 time points: baseline, week 6, and week 12. The primary outcome was change in the neurotoxicity score between these time points. Results: Of 33 patients approached for consent, 28 (85%) provided consent and were enrolled. The FACT/GOG-Ntx questionnaire was completed by 28 (100%) at baseline, 25 (89%) at week 6, and 24 (86%) at week 12. Average (standard deviation) neurotoxicity scores were 36.5 (6.6) at baseline, 34.0 (8.3) at week 6, and 30.6 (7.6) at week 12. Neurotoxicity scores changed from baseline by − 2.7 points (95% CI − 5.5 to 0.1; p = 0.061) at week 6 and − 6.0 points (95% CI − 5.6 to − 0.8; p = 0.012) at week 12. Clinically meaningful declines (decrease of > 10% from baseline) in neurotoxicity score were detected in 36% (9 of 25) at week 6 and in 67% (16 of 24) at week 12. Conclusion: Sixty-seven percent of patients experienced clinically significant CIPN within 12 weeks of starting chemotherapy. Feasibility metrics for enrollment, consent, CIPN assessment, and follow-up were met.

Original languageEnglish (US)
Pages (from-to)1901-1912
Number of pages12
JournalSupportive Care in Cancer
Volume28
Issue number4
DOIs
StatePublished - Apr 1 2020

Keywords

  • Alpha lipoic acid
  • Chemotherapy-induced peripheral neuropathy (CIPN)
  • Functional Assessment of cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx)
  • Lymphoma
  • Myeloma
  • Over-the-counter (OTC)
  • Pyridoxine (vitamin B6)
  • Thiamine (vitamin B1)

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma: a prospective, single-center, observational study'. Together they form a unique fingerprint.

  • Cite this